Trials / Completed
CompletedNCT03711331
Impact of a Strategy Based on Bacterial DNA Detection to Optimize Antibiotics in Patients With Hospital-acquired Pneumonia
Impact of a Strategy Based on the Unyvero® Testing System on Appropriate and Targeted Antimicrobial Treatment in Patients With Suspected VAP or HAP Requiring Mechanical Ventilation: a Randomized Controlled Unblinded Trial
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 161 (actual)
- Sponsor
- University Hospital, Lille · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
VAPERO is a randomized, unblinded, controlled study to measure the impact of a strategy based on the Unyvero® multiplex PCR test on the adjustment of antimicrobial therapy in patients suspected with ventilator-associated or hospital-acquired pneumonia (VAP/HAP) requiring mechanical ventilation. The gold-standard microbiological diagnostic method for pneumonia in the ICU is still culture-based identification and antimicrobial susceptibility testing (AST) despite being more than a hundred years old, with results turnaround time spanning over several days, exposing patients to potentially inappropriate broad-spectrum antimicrobial therapy. The investigators aim to measure the impact of the Unyvero® testing strategy to improve the percentage of patients with VAP or HAP receiving early targeted antimicrobial therapy compared to standard care.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | FilmArray® Pneumonia panel plus | Early adjustment of antimicrobial therapy according to the results of the Unyvero® testing for patients suspected with VAP or HAP requiring MV. |
| OTHER | Standard care | Standard care, with broad-spectrum antimicrobial therapy unchanged until reception of traditional microbiology results |
Timeline
- Start date
- 2020-06-16
- Primary completion
- 2023-09-22
- Completion
- 2023-09-22
- First posted
- 2018-10-18
- Last updated
- 2026-04-07
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT03711331. Inclusion in this directory is not an endorsement.